JOINT FILING AGREEMENT
Exhibit 99.3
The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for
the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the
information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to
the joint filing with each other on behalf of each of them of such a statement on Schedule 13D with respect to the common stock of Zynerba Pharmaceuticals, Inc. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.
IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 24th day of August, 2023.
|
Date: August 24, 2023
|
||
|
By:
|
/s/ Xxxxxx Xxxxxxx
|
|
|
Name:
|
Xxxxxx Xxxxxxx
|
|
|
Title:
|
Chief Financial Officer
|
|
|
Date: August 24, 2023
|
XYLOPHONE ACQUISITION CORP.
|
|
|
By:
|
/s/ Xxxxxx Xxxxxxx
|
|
|
Name:
|
Xxxxxx Xxxxxxx
|
|
|
Title:
|
Chief Executive Officer
|
|
